Literature DB >> 6204931

An anti-mouse macrophage monoclonal antibody reacting with T-derived leukaemic cells.

A Martin, A M Chevrinais, D Bourel, R Fauchet, B Genetet, L Toujas.   

Abstract

Hybridomas secreting anti-mouse macrophage antibodies were obtained by fusing a murine plasmacytoma with lymphocytes of a rat immunized against mouse macrophages. An IgM, monoclonal antibody (3 A 35) reacted with mouse monocytes, macrophages and polymorphonuclear leucocytes. It did not bind appreciably to erythrocytes, platelets and unstimulated T or B lymphocytes. However, 3 A 35 bound to various murine T-derived leukaemic cells and to a small proportion of Con A-stimulated thymocytes. Cross absorption experiments confirmed the existence of a common antigenic determinant on macrophages and leukaemic cells. The possibility that 3 A 35 identified a previously described antigen common to macrophages and normal or leukaemic T cells was investigated. The antibody was tested against thymocytes and macrophages of various mouse strains, some congenic for H-2 or T1a. The 3 A 35-detected antigen was found to be different from Ly5, Tla and Qa and did not represent a I-J encoded allotypic specificity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6204931      PMCID: PMC1454483     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  ANTIGENIC PROPERTIES OF EXPERIMENTAL LEUKEMIAS. I. SEROLOGICAL STUDIES IN VITRO WITH SPONTANEOUS AND RADIATION-INDUCED LEUKEMIAS.

Authors:  L J OLD; E A BOYSE
Journal:  J Natl Cancer Inst       Date:  1963-10       Impact factor: 13.506

2.  Cytolytic and cytostatic activity on tumor cells of circulating human monocytes.

Authors:  A Mantovani; T R Jerrells; J H Dean; R B Herberman
Journal:  Int J Cancer       Date:  1979-01-15       Impact factor: 7.396

3.  The G (Gross) leukemia antigen.

Authors:  L J Old; E A Boyse; E Stockert
Journal:  Cancer Res       Date:  1965-07       Impact factor: 12.701

4.  Antibodies to major histocompatibility antigens produced by hybrid cell lines.

Authors:  G Galfre; S C Howe; C Milstein; G W Butcher; J C Howard
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

5.  Transformation of granulocytes to macrophages in bone marrow colonies in vitro.

Authors:  D Metcalf
Journal:  J Cell Physiol       Date:  1971-04       Impact factor: 6.384

6.  Mac-1: a macrophage differentiation antigen identified by monoclonal antibody.

Authors:  T Springer; G Galfré; D S Secher; C Milstein
Journal:  Eur J Immunol       Date:  1979-04       Impact factor: 5.532

7.  The expression of Ia antigenic determinants on macrophages required for the in vitro antibody response.

Authors:  J E Niederhuber; P Allen; L Mayo
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

8.  Resistance to tumor graft in mice treated with inactivated Brucella abortus cultured in smooth or rough phase.

Authors:  A Martin; L Toujas; Y Le Garrec; L Dazord; J Amice
Journal:  J Natl Cancer Inst       Date:  1979-01       Impact factor: 13.506

9.  A new I subregion (I-J) marked by a locus (Ia-4) controlling surface determinants on suppressor T lymphocytes.

Authors:  D B Murphy; L A Herzenberg; K Okumura; L A Herzenberg; H O McDevitt
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

10.  Selective expression of H-2 (i-region) loci controlling determinants on helper and suppressor T lymphocytes.

Authors:  K Okumura; L A Herzenberg; D B Murphy; H O McDevitt; L A Herzenberg
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

View more
  2 in total

1.  Specific surface antigens expressed on activated mouse peritoneal macrophages and recognized by a novel monoclonal antibody.

Authors:  A Someya
Journal:  Immunology       Date:  1985-12       Impact factor: 7.397

2.  Modulation of expression of mouse macrophage surface antigens by monoclonal antibodies.

Authors:  B Collet; A Martin; G Merdrignac; B Genetet; L Toujas
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.